Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Saved in:
| Title: | Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. |
|---|---|
| Authors: | Kater AP; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Kersting S; Department of Hematology, HAGA Hospital, The Hague, The Netherlands., van Norden Y; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Dubois J; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Dobber JA; Laboratory Special Hematology and., Mellink CH; Laboratory of Cytogenetics, Academic Medical Center, Amsterdam, The Netherlands., Evers LM; Laboratory Special Hematology and., Croon-de Boer F; Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands., Schreurs J; Internal Medicine, Martini Hospital, Groningen, The Netherlands., van der Spek E; Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands., Visser H; Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands., Idink C; Internal Medicine, ZorgSaam Hospital, Terneuzen, The Netherlands., Wittebol S; Internal Medicine, Gelderland Valley Hospital, Ede, The Netherlands., Hoogendoorn M; Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Tonino SH; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Mobasher M; Genentech, Inc, South San Francisco, CA; and., Levin MD; Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. |
| Corporate Authors: | HOVON CLL study group. |
| Source: | Blood advances [Blood Adv] 2018 Dec 26; Vol. 2 (24), pp. 3566-3571. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
